Global Pet Cancer Therapeutics

Pet Cancer Therapeutics Comprehensive Study by Type (Chemotherapy Drugs, Vaccines), Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others), Treatment (Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy), Animal (Dog, Cat, Other Animals) Players and Region - Global Market Outlook to 2026

Pet Cancer Therapeutics Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 12.76%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Over the past few decades, global pet cancer prevalence has been increased drastically, which will ultimately upsurge the demand for Pet Cancer Therapeutics. In addition to this, increasing spending on Animal care and growing awareness and routine checkups for the animals will ultimately upsurge the demand for the same. Moreover, the inclusion of technologically advanced therapies such as Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy, and many others will create vigorous opportunities for pet cancer treatments.
According to AMA, the market for Pet Cancer Therapeutics is expected to register a CAGR of 12.76% during the forecast period to 2026. This growth is primarily driven by Upsurging Investments in Animal Care and Increasing Prevalence of Pet Cancer across the Globe.

Globally, a noticeable market trend is evident Increasing Technological Enhancements In Treatments for Mast Cell Cancer and Melanoma . The Diseases & Therapeutic Areas sector in the North Amercia region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Aratana Therapeutics Inc (United States), AB Science (France), Boehringer Ingelheim International GmbH (Germany), Nippon Zenyaku Kogyo Co.Ltd. (Japan), Morphogenesis Inc. (United States), VetDC, Inc. (United States), Karyopharm Therapeutics Inc. (United States), Rhizen Pharmaceuticals SA (Switzerland), Regeneus Ltd (Australia) and Oasmia Pharmaceutical AB (Sweden) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In April 2019, Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics, pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats.
In April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment. Moreover, in Jan 2018, Aratana Therapeutics has been granted conditional approval for its canine osteosarcoma vaccine, Live Listeria Vector(AT-014), by the USDA's Center for Veterinary Biologics.

Regulatory Insights:
The government of the United States has mandated to register the pet care pharmaceutical products as well as other pesticide products with the US Environmental Protection Agency (EPA) and with each state where the product is sold.

Market Drivers
  • Upsurging Investments in Animal Care
  • Increasing Prevalence of Pet Cancer across the Globe

Market Trend
  • Increasing Technological Enhancements In Treatments for Mast Cell Cancer and Melanoma
  • Introduction to Internet / Mobile Pet Care will Simplify Pet Care Treatments

Restraints
  • Lack of Awareness from the Underdeveloped Regions
  • Escalating Prices for Cancer Treatment Products across the Globe

Opportunities
Improved Pet Care Infrastructure across Emerging Economies and Favorable Government Reimbursement in Pet Cancer Therapeutics
Challenges
Stringent Government Regulations related to Cancer Therapeutics Development

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Pet Cancer Therapeutics Study Sheds Light on
— The Pet Cancer Therapeutics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Pet Cancer Therapeutics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Pet Cancer Therapeutics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Chemotherapy Drugs
  • Vaccines
By Application
  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary
  • Squamous Cell Cancer
  • Others
By Treatment
  • Chemotherapy
  • Targeted Therapy
  • Combination Therapy
  • Immunotherapy

By Animal
  • Dog
  • Cat
  • Other Animals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Upsurging Investments in Animal Care
      • 3.2.2. Increasing Prevalence of Pet Cancer across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations related to Cancer Therapeutics Development
    • 3.4. Market Trends
      • 3.4.1. Increasing Technological Enhancements In Treatments for Mast Cell Cancer and Melanoma
      • 3.4.2. Introduction to Internet / Mobile Pet Care will Simplify Pet Care Treatments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pet Cancer Therapeutics, by Type, Application, Treatment, Animal and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pet Cancer Therapeutics (Value)
      • 5.2.1. Global Pet Cancer Therapeutics by: Type (Value)
        • 5.2.1.1. Chemotherapy Drugs
        • 5.2.1.2. Vaccines
      • 5.2.2. Global Pet Cancer Therapeutics by: Application (Value)
        • 5.2.2.1. Lymphoma
        • 5.2.2.2. Mast Cell Cancer
        • 5.2.2.3. Melanoma
        • 5.2.2.4. Mammary
        • 5.2.2.5. Squamous Cell Cancer
        • 5.2.2.6. Others
      • 5.2.3. Global Pet Cancer Therapeutics by: Treatment (Value)
        • 5.2.3.1. Chemotherapy
        • 5.2.3.2. Targeted Therapy
        • 5.2.3.3. Combination Therapy
        • 5.2.3.4. Immunotherapy
      • 5.2.4. Global Pet Cancer Therapeutics by: Animal (Value)
        • 5.2.4.1. Dog
        • 5.2.4.2. Cat
        • 5.2.4.3. Other Animals
      • 5.2.5. Global Pet Cancer Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Pet Cancer Therapeutics (Price)
      • 5.3.1. Global Pet Cancer Therapeutics by: Type (Price)
  • 6. Pet Cancer Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Aratana Therapeutics Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AB Science (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nippon Zenyaku Kogyo Co.Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Morphogenesis Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. VetDC, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Karyopharm Therapeutics Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Rhizen Pharmaceuticals SA (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Regeneus Ltd (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Oasmia Pharmaceutical AB (Sweden)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pet Cancer Therapeutics Sale, by Type, Application, Treatment, Animal and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pet Cancer Therapeutics (Value)
      • 7.2.1. Global Pet Cancer Therapeutics by: Type (Value)
        • 7.2.1.1. Chemotherapy Drugs
        • 7.2.1.2. Vaccines
      • 7.2.2. Global Pet Cancer Therapeutics by: Application (Value)
        • 7.2.2.1. Lymphoma
        • 7.2.2.2. Mast Cell Cancer
        • 7.2.2.3. Melanoma
        • 7.2.2.4. Mammary
        • 7.2.2.5. Squamous Cell Cancer
        • 7.2.2.6. Others
      • 7.2.3. Global Pet Cancer Therapeutics by: Treatment (Value)
        • 7.2.3.1. Chemotherapy
        • 7.2.3.2. Targeted Therapy
        • 7.2.3.3. Combination Therapy
        • 7.2.3.4. Immunotherapy
      • 7.2.4. Global Pet Cancer Therapeutics by: Animal (Value)
        • 7.2.4.1. Dog
        • 7.2.4.2. Cat
        • 7.2.4.3. Other Animals
      • 7.2.5. Global Pet Cancer Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Pet Cancer Therapeutics (Price)
      • 7.3.1. Global Pet Cancer Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pet Cancer Therapeutics: by Type(USD Million)
  • Table 2. Pet Cancer Therapeutics Chemotherapy Drugs , by Region USD Million (2015-2020)
  • Table 3. Pet Cancer Therapeutics Vaccines , by Region USD Million (2015-2020)
  • Table 4. Pet Cancer Therapeutics: by Application(USD Million)
  • Table 5. Pet Cancer Therapeutics Lymphoma , by Region USD Million (2015-2020)
  • Table 6. Pet Cancer Therapeutics Mast Cell Cancer , by Region USD Million (2015-2020)
  • Table 7. Pet Cancer Therapeutics Melanoma , by Region USD Million (2015-2020)
  • Table 8. Pet Cancer Therapeutics Mammary , by Region USD Million (2015-2020)
  • Table 9. Pet Cancer Therapeutics Squamous Cell Cancer , by Region USD Million (2015-2020)
  • Table 10. Pet Cancer Therapeutics Others , by Region USD Million (2015-2020)
  • Table 11. Pet Cancer Therapeutics: by Treatment(USD Million)
  • Table 12. Pet Cancer Therapeutics Chemotherapy , by Region USD Million (2015-2020)
  • Table 13. Pet Cancer Therapeutics Targeted Therapy , by Region USD Million (2015-2020)
  • Table 14. Pet Cancer Therapeutics Combination Therapy , by Region USD Million (2015-2020)
  • Table 15. Pet Cancer Therapeutics Immunotherapy , by Region USD Million (2015-2020)
  • Table 16. Pet Cancer Therapeutics: by Animal(USD Million)
  • Table 17. Pet Cancer Therapeutics Dog , by Region USD Million (2015-2020)
  • Table 18. Pet Cancer Therapeutics Cat , by Region USD Million (2015-2020)
  • Table 19. Pet Cancer Therapeutics Other Animals , by Region USD Million (2015-2020)
  • Table 20. South America Pet Cancer Therapeutics, by Country USD Million (2015-2020)
  • Table 21. South America Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 22. South America Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 23. South America Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 24. South America Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 25. Brazil Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 26. Brazil Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 27. Brazil Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 28. Brazil Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 29. Argentina Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 30. Argentina Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 31. Argentina Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 32. Argentina Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 33. Rest of South America Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 36. Rest of South America Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 37. Asia Pacific Pet Cancer Therapeutics, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 41. Asia Pacific Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 42. China Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 43. China Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 44. China Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 45. China Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 46. Japan Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 47. Japan Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 48. Japan Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 49. Japan Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 50. India Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 51. India Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 52. India Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 53. India Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 54. South Korea Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 55. South Korea Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 56. South Korea Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 57. South Korea Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 58. Taiwan Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 59. Taiwan Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 60. Taiwan Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 61. Taiwan Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 62. Australia Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 63. Australia Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 64. Australia Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 65. Australia Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 70. Europe Pet Cancer Therapeutics, by Country USD Million (2015-2020)
  • Table 71. Europe Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 72. Europe Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 73. Europe Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 74. Europe Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 75. Germany Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 76. Germany Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 77. Germany Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 78. Germany Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 79. France Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 80. France Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 81. France Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 82. France Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 83. Italy Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 84. Italy Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 85. Italy Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 86. Italy Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 87. United Kingdom Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 90. United Kingdom Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 91. Netherlands Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 92. Netherlands Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 93. Netherlands Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 94. Netherlands Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 95. Rest of Europe Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 98. Rest of Europe Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 99. MEA Pet Cancer Therapeutics, by Country USD Million (2015-2020)
  • Table 100. MEA Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 101. MEA Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 102. MEA Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 103. MEA Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 104. Middle East Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 105. Middle East Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 106. Middle East Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 107. Middle East Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 108. Africa Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 109. Africa Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 110. Africa Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 111. Africa Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 112. North America Pet Cancer Therapeutics, by Country USD Million (2015-2020)
  • Table 113. North America Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 114. North America Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 115. North America Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 116. North America Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 117. United States Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 118. United States Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 119. United States Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 120. United States Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 121. Canada Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 122. Canada Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 123. Canada Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 124. Canada Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 125. Mexico Pet Cancer Therapeutics, by Type USD Million (2015-2020)
  • Table 126. Mexico Pet Cancer Therapeutics, by Application USD Million (2015-2020)
  • Table 127. Mexico Pet Cancer Therapeutics, by Treatment USD Million (2015-2020)
  • Table 128. Mexico Pet Cancer Therapeutics, by Animal USD Million (2015-2020)
  • Table 129. Pet Cancer Therapeutics: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Pet Cancer Therapeutics: by Type(USD Million)
  • Table 141. Pet Cancer Therapeutics Chemotherapy Drugs , by Region USD Million (2021-2026)
  • Table 142. Pet Cancer Therapeutics Vaccines , by Region USD Million (2021-2026)
  • Table 143. Pet Cancer Therapeutics: by Application(USD Million)
  • Table 144. Pet Cancer Therapeutics Lymphoma , by Region USD Million (2021-2026)
  • Table 145. Pet Cancer Therapeutics Mast Cell Cancer , by Region USD Million (2021-2026)
  • Table 146. Pet Cancer Therapeutics Melanoma , by Region USD Million (2021-2026)
  • Table 147. Pet Cancer Therapeutics Mammary , by Region USD Million (2021-2026)
  • Table 148. Pet Cancer Therapeutics Squamous Cell Cancer , by Region USD Million (2021-2026)
  • Table 149. Pet Cancer Therapeutics Others , by Region USD Million (2021-2026)
  • Table 150. Pet Cancer Therapeutics: by Treatment(USD Million)
  • Table 151. Pet Cancer Therapeutics Chemotherapy , by Region USD Million (2021-2026)
  • Table 152. Pet Cancer Therapeutics Targeted Therapy , by Region USD Million (2021-2026)
  • Table 153. Pet Cancer Therapeutics Combination Therapy , by Region USD Million (2021-2026)
  • Table 154. Pet Cancer Therapeutics Immunotherapy , by Region USD Million (2021-2026)
  • Table 155. Pet Cancer Therapeutics: by Animal(USD Million)
  • Table 156. Pet Cancer Therapeutics Dog , by Region USD Million (2021-2026)
  • Table 157. Pet Cancer Therapeutics Cat , by Region USD Million (2021-2026)
  • Table 158. Pet Cancer Therapeutics Other Animals , by Region USD Million (2021-2026)
  • Table 159. South America Pet Cancer Therapeutics, by Country USD Million (2021-2026)
  • Table 160. South America Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 161. South America Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 162. South America Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 163. South America Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 164. Brazil Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 165. Brazil Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 166. Brazil Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 167. Brazil Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 168. Argentina Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 169. Argentina Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 170. Argentina Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 171. Argentina Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 172. Rest of South America Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 175. Rest of South America Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 176. Asia Pacific Pet Cancer Therapeutics, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 180. Asia Pacific Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 181. China Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 182. China Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 183. China Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 184. China Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 185. Japan Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 186. Japan Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 187. Japan Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 188. Japan Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 189. India Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 190. India Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 191. India Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 192. India Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 193. South Korea Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 194. South Korea Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 195. South Korea Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 196. South Korea Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 197. Taiwan Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 198. Taiwan Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 199. Taiwan Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 200. Taiwan Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 201. Australia Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 202. Australia Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 203. Australia Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 204. Australia Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 209. Europe Pet Cancer Therapeutics, by Country USD Million (2021-2026)
  • Table 210. Europe Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 211. Europe Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 212. Europe Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 213. Europe Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 214. Germany Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 215. Germany Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 216. Germany Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 217. Germany Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 218. France Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 219. France Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 220. France Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 221. France Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 222. Italy Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 223. Italy Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 224. Italy Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 225. Italy Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 226. United Kingdom Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 229. United Kingdom Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 230. Netherlands Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 231. Netherlands Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 232. Netherlands Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 233. Netherlands Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 234. Rest of Europe Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 237. Rest of Europe Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 238. MEA Pet Cancer Therapeutics, by Country USD Million (2021-2026)
  • Table 239. MEA Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 240. MEA Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 241. MEA Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 242. MEA Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 243. Middle East Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 244. Middle East Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 245. Middle East Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 246. Middle East Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 247. Africa Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 248. Africa Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 249. Africa Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 250. Africa Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 251. North America Pet Cancer Therapeutics, by Country USD Million (2021-2026)
  • Table 252. North America Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 253. North America Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 254. North America Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 255. North America Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 256. United States Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 257. United States Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 258. United States Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 259. United States Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 260. Canada Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 261. Canada Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 262. Canada Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 263. Canada Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 264. Mexico Pet Cancer Therapeutics, by Type USD Million (2021-2026)
  • Table 265. Mexico Pet Cancer Therapeutics, by Application USD Million (2021-2026)
  • Table 266. Mexico Pet Cancer Therapeutics, by Treatment USD Million (2021-2026)
  • Table 267. Mexico Pet Cancer Therapeutics, by Animal USD Million (2021-2026)
  • Table 268. Pet Cancer Therapeutics: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pet Cancer Therapeutics: by Type USD Million (2015-2020)
  • Figure 5. Global Pet Cancer Therapeutics: by Application USD Million (2015-2020)
  • Figure 6. Global Pet Cancer Therapeutics: by Treatment USD Million (2015-2020)
  • Figure 7. Global Pet Cancer Therapeutics: by Animal USD Million (2015-2020)
  • Figure 8. South America Pet Cancer Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Pet Cancer Therapeutics Share (%), by Country
  • Figure 10. Europe Pet Cancer Therapeutics Share (%), by Country
  • Figure 11. MEA Pet Cancer Therapeutics Share (%), by Country
  • Figure 12. North America Pet Cancer Therapeutics Share (%), by Country
  • Figure 13. Global Pet Cancer Therapeutics: by Type USD/Units (2015-2020)
  • Figure 14. Global Pet Cancer Therapeutics share by Players 2020 (%)
  • Figure 15. Global Pet Cancer Therapeutics share by Players (Top 3) 2020(%)
  • Figure 16. Global Pet Cancer Therapeutics share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Aratana Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Aratana Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 20. AB Science (France) Revenue, Net Income and Gross profit
  • Figure 21. AB Science (France) Revenue: by Geography 2020
  • Figure 22. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2020
  • Figure 24. Nippon Zenyaku Kogyo Co.Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Nippon Zenyaku Kogyo Co.Ltd. (Japan) Revenue: by Geography 2020
  • Figure 26. Morphogenesis Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Morphogenesis Inc. (United States) Revenue: by Geography 2020
  • Figure 28. VetDC, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. VetDC, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Karyopharm Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Karyopharm Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Rhizen Pharmaceuticals SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Rhizen Pharmaceuticals SA (Switzerland) Revenue: by Geography 2020
  • Figure 34. Regeneus Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 35. Regeneus Ltd (Australia) Revenue: by Geography 2020
  • Figure 36. Oasmia Pharmaceutical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 37. Oasmia Pharmaceutical AB (Sweden) Revenue: by Geography 2020
  • Figure 38. Global Pet Cancer Therapeutics: by Type USD Million (2021-2026)
  • Figure 39. Global Pet Cancer Therapeutics: by Application USD Million (2021-2026)
  • Figure 40. Global Pet Cancer Therapeutics: by Treatment USD Million (2021-2026)
  • Figure 41. Global Pet Cancer Therapeutics: by Animal USD Million (2021-2026)
  • Figure 42. South America Pet Cancer Therapeutics Share (%), by Country
  • Figure 43. Asia Pacific Pet Cancer Therapeutics Share (%), by Country
  • Figure 44. Europe Pet Cancer Therapeutics Share (%), by Country
  • Figure 45. MEA Pet Cancer Therapeutics Share (%), by Country
  • Figure 46. North America Pet Cancer Therapeutics Share (%), by Country
  • Figure 47. Global Pet Cancer Therapeutics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Aratana Therapeutics Inc (United States)
  • AB Science (France)
  • Boehringer Ingelheim International GmbH (Germany)
  • Nippon Zenyaku Kogyo Co.Ltd. (Japan)
  • Morphogenesis Inc. (United States)
  • VetDC, Inc. (United States)
  • Karyopharm Therapeutics Inc. (United States)
  • Rhizen Pharmaceuticals SA (Switzerland)
  • Regeneus Ltd (Australia)
  • Oasmia Pharmaceutical AB (Sweden)
Additional players considered in the study are as follows:
Zoetis Inc (United States) , Torigen Pharmaceuticals, Inc. (United States) , CanFel Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 233 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pet Cancer Therapeutics Quantitative research analysis
Global Pet Cancer Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pet Cancer Therapeutics market is expected to see a CAGR of 12.76% during projected year 2020 to 2026.
Top performing companies in the Global Pet Cancer Therapeutics market are Aratana Therapeutics Inc (United States), AB Science (France), Boehringer Ingelheim International GmbH (Germany), Nippon Zenyaku Kogyo Co.Ltd. (Japan), Morphogenesis Inc. (United States), VetDC, Inc. (United States), Karyopharm Therapeutics Inc. (United States), Rhizen Pharmaceuticals SA (Switzerland), Regeneus Ltd (Australia) and Oasmia Pharmaceutical AB (Sweden), to name a few.
North Amercia is dominating the Pet Cancer Therapeutics Market.

Know More About Global Pet Cancer Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Influenza Diagnostics Comprehensive Study by Type (Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Cu...
$ 3450
Prosthetic Heart Valves Comprehensive Study by Type (Transcatheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve), End User (Hospitals, Ambulatory Surgical Centers, Others) Players and Regi...
$ 3500
Cystoscope Comprehensive Study by Type (Rigid Cystoscope, Flexible Cystoscope), Application (Urology, Gynaecology), End User (Hospitals & Clinics, Ambulatory Surgical Centers) Players and Region - Gl...
$ 3500
Diuretics Comprehensive Study by Type (Thiazide diuretics, Loop diuretics, Potassium-sparing diuretics), Application (Hypertension, Edema, Hypercalciuria, Diabetes, Insipidus, Others), Distribution C...
$ 3750
Therapeutic Vaccines Comprehensive Study by Category (Antigen Vaccines, Dendritic Cell Vaccines, DNA Vaccines, Tumor Cell Vaccines), Disease (Autoimmune Disease, Cancer, Neurological Diseases, Infect...
$ 3650
Traumatic Brain Injury Therapeutics Comprehensive Study by Type (Immediate emergency care, Medications (Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-...
$ 3800